Progressive Resistance Training and Cancer Testis (PROTRACT) - Efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial
Open Access
- 1 August 2011
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 326
Abstract
Standard treatment for patients with disseminated germ cell tumors is combination chemotherapy with bleomycin, etoposide and cisplatin (BEP). This treatment is highly effective, but the majority of patients experience severe adverse effects during treatment and are at risk of developing considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, and pulmonary toxicity. One neglected side effect is the significant muscular fatigue mentioned by many patients with testicular cancer both during and after treatment. Very limited information exists concerning the patho-physiological effects of antineoplastic agents on skeletal muscle. The primary aim of this study is to investigate the effects of BEP-treatment on the skeletal musculature in testicular cancer patients, and to examine whether the expected treatment-induced muscular deterioration can be attenuated or even reversed by high intensity progressive resistance training (HIPRT).Keywords
This publication has 55 references indexed in Scilit:
- Benefits of exercise training on breast cancer progression and inflammation in C3(1)SV40Tag miceCytokine, 2011
- Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscleJournal of Applied Physiology, 2011
- Testicular Cancer Survivorship: Research Strategies and RecommendationsJNCI: Journal of the National Cancer Institute, 2010
- Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trialBMJ, 2009
- Direct effects of doxorubicin on skeletal muscle contribute to fatigueBritish Journal of Cancer, 2009
- Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 dataThe Lancet Oncology, 2007
- Suppression of testosterone does not blunt mRNA expression of myoD, myogenin, IGF, myostatin or androgen receptor post strength training in humansThe Journal of Physiology, 2007
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- A new method for measuring power output in a single leg extension: feasibility, reliability and validityEuropean Journal of Applied Physiology, 1990